stockrowInsmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.
- Revenue
- +268.4%
- EPS
- +73.8%
- Free cash flow
- +81.1%
- Total debt
- +0.27%
Quarter to September 2026, against a year earlier
Follow INSM
Alert me
Insmed, Inc. (INSM) Revenue growth
Insmed, Inc.'s revenue growth over the twelve months to 30 September 2026 was 240.0%, up 173.2 percentage points from fiscal 2025 (66.7%). Over the past ten years it has ranged from −14.5% (fiscal 2018) to 1,287.6% (fiscal 2019); the current reading is higher than 88% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 66.7% | 47.56 |
| FY2024 | 19.2% | (5.22) |
| FY2023 | 24.4% | (5.80) |
| FY2022 | 30.2% | 15.56 |
| FY2021 | 14.6% | (5.85) |
| FY2020 | 20.5% | (1,267.08) |
| FY2019 | 1,287.6% | 1,302.04 |
| FY2018 | −14.5% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 268.4% | (27.68) |
| Jun 2026 | 296.1% | 66.49 |
| Mar 2026 | 229.6% | 77.00 |
| Dec 2025 | 152.6% | 100.26 |
| 27 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| INSM Insmed, Inc. | 240.0% |
| BBIO BridgeBio Pharma, Inc. compare | 167.3% |
| ASND Ascendis Pharma A/S compare | 126.0% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 56.2% |
| INCY Incyte Corporation compare | 24.9% |
| GMAB Genmab A/S Sponsored ADR compare | 22.3% |
| EXEL Exelixis, Inc. compare | 9.12% |
| BNTX BioNTech SE Sponsored ADR compare | −22.7% |
| ROIV Roivant Sciences Ltd. compare | −67.6% |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on INSM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement